melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Our Services
High Throughput In Vivo Pharmacology:
Discovery Services:
Our Technology
 

theraTRACE

Melior Pharmaceuticals

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery scientific advisors

 
   

Christopher Lipinski, Ph.D

Dr. Lipinski is a medicinal chemist with more than 34 years of experience at Pfizer, Inc. In 2002 he retired from the highest scientific position in the worldwide Pfizer research organization (Senior Research Fellow) and now serves as a Drug-Like Properties consultant to Pfizer. Dr. Lipinski is renowned for his "Rule of Five"; an algorithm for predicting drug compounds likely to show oral activity (See Appendix B). His 1997 publication in "Advanced Drug Delivery Reviews", where the "Rule of Five" first appears, is the most frequently cited medicinal chemistry paper in the last decade and is one of the most cited publications in the journal's history. He was recipient of the American Chemical Societies 2004 Medicinal Chemistry award.

Dr Lipinski is a member of the Medicinal Chemistry section of the American Chemical Society, the American Association of Pharmaceutical Sciences, the Society for Biomolecular Screening and the European Federation of Pharmaceutical Sciences. He serves on scientific advisory boards for the Global Alliance for Tuberculosis Drug Development, ASDI Biosciences, Advanced Chemistry Development Labs and the Matrical Company. Dr. Lipinski is a consultant for Symyx and the Hereditary Disease Foundation. He is a member of the editorial board of the journal of Pharmaceutical Sciences, Current Drug Discovery Technology, the highlights advisory board of Nature Reviews Drug Discovery, as well as the advisory boards of several other journals. He serves on the Conference Advisory Board for Cambridge Healthtech Institute. Since 1984, he has been an adjunct faculty member at Connecticut College in New London CT, and has over 180 publications and invited presentations and 17 issued US patents.

Dr. Lipinski received a B.Sc. degree in chemistry from San Francisco State College in 1965 and a Ph.D. in 1968 in physical organic chemistry from the University of California, Berkeley. He joined Pfizer in 1970 following a National Institutes of General Medical Sciences Postdoctoral Fellowship at the California Institute of Technology.

melior

Robert A. Ronfeld, Ph.D

Dr. Ronfeld has 25 year of experience in the pharmaceutical industry working in human and veterinary medicine, in both discovery and development. He spent 20 years at Pfizer in Groton, CT before retiring in 2001. Presently he consults part-time on short-term projects in pharmaceutical research and development, primarily with biotech companies. At Pfizer he had numerous scientific and leadership roles. He led the Drug Metabolism Department (1990-1998) as it grew substantially and increased its discovery involvement, its utilization of in vitro methods and technology, mass spectrometry and the prediction of human pharmacokinetics from preclinical and in vitro data. He also led the development of a Clinical Pharmacokinetics and Pharmacodynamics group within Clinical Research prior to retiring. He has many years of experience in the multi-disciplinary and strategic aspects of drug development and worked on therapeutic, management and process improvement teams. During his time at Pfizer, he was responsible for the pharmacokinetic and drug metabolism sections for several NSA regulatory submissions. He has served on the editorial boards of the journals, Drug Metabolism and Disposition, Current Drug Metabolism, and Journal of Pharmaceutical Sciences. He received his PhD in Pharmacokinetics from the University of California at San Francisco in 1974.

Back to top of page